Taylor H G, Butler W M, Rhoads J, Karcher D S, Detrick-Hooks B
Cancer. 1982 Apr 15;49(8):1524-9. doi: 10.1002/1097-0142(19820415)49:8<1524::aid-cncr2820490803>3.0.co;2-u.
Prolymphocytic leukemia (PL) is a clinically distinct leukemic disorder. Cytochemical and surface marker characteristics help to differentiate PL from other types of leukemia, including chronic lymphocytic leukemia (CLL). In contrast to patients with CLL, those with PL frequently require early therapeutic intervention. Standard treatment regimens for CLL as well as splenectomy and splenic irradiation have not been effective in the treatment of PL. Combination chemotherapy with cyclophosphamide, Doxorubicin, vincristine, and prednisone (CHOP) has produced impressive clinical responses in patients with PL. The treatment of a patient with PL is discussed and the literature is reviewed.
幼淋巴细胞白血病（PL）是一种临床上独特的白血病性疾病。细胞化学和表面标志物特征有助于将PL与其他类型的白血病区分开来，包括慢性淋巴细胞白血病（CLL）。与CLL患者不同，PL患者经常需要早期治疗干预。CLL的标准治疗方案以及脾切除术和脾照射对PL治疗均无效。环磷酰胺、多柔比星、长春新碱和泼尼松联合化疗（CHOP）已在PL患者中产生了令人印象深刻的临床反应。本文讨论了一名PL患者的治疗情况并回顾了相关文献。
